US President Donald Trump’s administration signed the Presidential Memorandum on Tuesday and announced Bloomberg’s intervention against pharmaceutical advertising in television and social media, which could disrupt billions of dollars in annual advertising.
According to the Memorandum report, Federal Health Agency requires that pharmaceutical companies require more side effects in their commercials and promote existing rules on misleading ads. Trump’s administration says that new measures aim to increase the transparency of patients.
Also read | Trump swims massive tariffs to China, India to push Russia
In addition to New Zealand, the US is the only place where pharmaceutical companies can directly advertise to consumers.
Although the new regulations would stop if the advertising was completely banned, Robert F Kennedy Jr.
However, the addition of stricter advertising requirements is likely to affect pharmaceutical companies and media companies that rely strongly on these advertising dollars.
In 2024, drug companies spent $ 10.8 billion on a direct consumer of pharmaceutical advertising, reported from the advertising data company Mediaradar and added that Abbvie and Pfizer Inc were particularly large expenses.
Abbvie himself spent $ 2 billion on direct consumer drug advertising in 2024, especially on the advertising of anti -inflammatory drugs of Skyrizi and Rinvoq. Drugs brought more than $ 6.5 billion for ABBVIE in the second quarter of 2025.
Abbvie could not be immediately addressed and refused to comment on Pfizer.
About misleading ads
In addition to the new regulations, the Food and Drug Administration (FDA) plans to enforce the existing rules on misleading advertising.
Also read | The Indian Pharmaceutical Sector needs to increase prices, web and IP transfers to deal with the uncertainty of tariffs: Message
“The FDA today sends approximately 100 letters of coercive measures and thousands of letters in the field, including online pharmacies that are increasingly promoting drugs without mentioning side effects,” Bloomberg quoted FDA Commissioner Marta Makara and said in a video published on social media.
Drug advertising claims that advertising can cause patients to talk to their doctors about health problems. Critics, however, point out that ads generally have expensive, branded drugs.
One of the officials said, as Reuters quoted, “there are ads that clearly exceed the border with regard to regulation, and I think any potential future legal steps, I think, quite clear.”
They said that AD drug recovery was increasingly lax, adding that the FDA in 2024 was not sending any letter letters about drug advertising. However, they did not publish which companies were recovered or warning letters.
The role of influencers of social media, television advertisements and telehealth companies
Meanwhile, Trump’s administration also examines the role that plays influence on social media in advertising drugs and whether they follow the same standards applied to television.
Administration also plans to close a gap that allows companies to pass patients to the website for side effect information.
“They will have to report all their side effects,” Kennedy said in an interview with Fox News on Tuesday evening. “In some cases, this could create an advertisement that is four minutes long.”
According to Mediaradar, 59% of the pharmaceutical industry expenditures in 2024 were in television advertising, making it the third highest industry.
Also read | It won’t be, it won’t – Trump’s tariff tartar has pharmaceutical investors on the edge of pharmaceutical investors
Another aspect in which Trump Administration closer to see is advertising from Telehealth companies that work differently from traditional pharmaceutical companies, Bloomberg added.
The administration did not name companies, but recorded the advertising Super Bowl from the Telehealth Society, which received criticism from the senators.
In early February, the Republican Senator Roger Marshall from Kansas and Democratic Senator Dick Durbin of Illinois sent a FDA letter on advertising on the Telehealth Company Hims & Hers Health Inc., which claimed that he could not publish key security and risk information.
Hims defended it and said he had not been inventing one treatment or solution, but focused on raising obesity awareness.
On Tuesday, Trump Administration mentioned a greater HHS, FDA, FDA, Federal Commercial Commission and the Ministry of Justice for advertising operated by Telehealth Society, and the influential influences of social media within its Make Health Health Again strategy.
(Tagstotranslate) Telehealth Companies (T) Pharmaceutical Advertising (T) FDA (T) Drug ADS (T) Hims & Hand Health Inc. ; Durbin
